The revised Sapporo criteria for APS require clinical features (thrombosis or pregnancy morbidity) and laboratory tests for LAC, IgG/IgM aCL, and/or IgG/IgM anti-β2GPI with at least two aPL tests performed at least 12 weeks apart [7,8]. The gene discussed is CD40LG; the disease is deep vein thrombosis.